Skip to content
Med Rx.

Clopidogrel + Aspirin + Streptokinase

Moderate 16 published sources

This interaction is documented in this data source.

Clopidogrel + Aspirin
Checked as Clopidogrel + Acetylsalicylic acid
Streptokinase
Checked as Streptokinase

2 documented mechanisms

This source documents more than one distinct mechanism for this pair. Each is shown with its own effect, advice and sources rather than merged into one.

  1. Mechanism 1: Synergy

    Moderate

    via Acetylsalicylic acid and Streptokinase

    What happens

    Drugs that inhibit platelet function may increase the risk of bleeding when administered prior to, during, or after thrombolytic therapy.

    What to do

    Careful monitoring for signs of bleeding, particularly at arterial puncture wounds, is recommended when thrombolytics are used concurrently or sequentially with antiplatelet agents other than aspirin. Some authorities recommend avoiding the initiation of platelet aggregation inhibitors within the first 24 hours following thrombolysis treatment.

    8 sources

    1. Harder S, Klinkhardt U "Thrombolytics: drug interactions of clinical significance." Drug Saf 23 (2000): 391-9
    2. "Product Information. TNKase (tenecteplase)" Genentech, South San Francisco, CA.
    3. "Product Information. Abbokinase (urokinase)." Abbott Pharmaceutical, Abbott Park, IL.
    4. "Product Information. Retavase (reteplase)." Boehringer Mannheim, Gaithersburg, MD.
    5. "Product Information. Ticlid (ticlopidine)." Syntex Laboratories Inc, Palo Alto, CA.
    6. "Product Information. Activase (alteplase)." Genentech, South San Francisco, CA.
    7. Hirsch J, Dalen J, Guyatt G, American College of Chest Physicians "The sixth (2000) ACCP guidelines for antithrombotic therapy for prevention and treatment of thrombosis. American College of Physicians." Chest 119(1 Suppl) (2001): 1S-2S
    8. "Product Information. Streptase (streptokinase)." Astra USA, Westborough, MA.

  2. Mechanism 2: Synergy

    Moderate

    via Clopidogrel and Streptokinase

    What happens

    Drugs that inhibit platelet function may increase the risk of bleeding when administered prior to, during, or after thrombolytic therapy.

    What to do

    Careful monitoring for signs of bleeding, particularly at arterial puncture wounds, is recommended when thrombolytics are used concurrently or sequentially with antiplatelet agents other than aspirin. Some authorities recommend avoiding the initiation of platelet aggregation inhibitors within the first 24 hours following thrombolysis treatment.

    8 sources

    1. Harder S, Klinkhardt U "Thrombolytics: drug interactions of clinical significance." Drug Saf 23 (2000): 391-9
    2. "Product Information. TNKase (tenecteplase)" Genentech, South San Francisco, CA.
    3. "Product Information. Abbokinase (urokinase)." Abbott Pharmaceutical, Abbott Park, IL.
    4. "Product Information. Retavase (reteplase)." Boehringer Mannheim, Gaithersburg, MD.
    5. "Product Information. Ticlid (ticlopidine)." Syntex Laboratories Inc, Palo Alto, CA.
    6. "Product Information. Activase (alteplase)." Genentech, South San Francisco, CA.
    7. Hirsch J, Dalen J, Guyatt G, American College of Chest Physicians "The sixth (2000) ACCP guidelines for antithrombotic therapy for prevention and treatment of thrombosis. American College of Physicians." Chest 119(1 Suppl) (2001): 1S-2S
    8. "Product Information. Streptase (streptokinase)." Astra USA, Westborough, MA.

Keep checking